These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33426751)

  • 1. Psychomotor processing and functional decline in Parkinson's disease predicted by the Purdue Pegboard test.
    Hinkle JT; Pontone GM
    Int J Geriatr Psychiatry; 2021 Jun; 36(6):909-916. PubMed ID: 33426751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construct validity of the 9-Hole Peg Test and Purdue Pegboard Test in people with mild to moderately severe Parkinson's disease.
    Proud EL; Miller KJ; Bilney B; Morris ME; McGinley JL
    Physiotherapy; 2020 Jun; 107():202-208. PubMed ID: 32026821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.
    Kostić V; Dzoljić E; Todorović Z; Mijajlović M; Svetel M; Stefanova E; Dragasević N; Petrović I; Milosević M; Kovacević I; Miljković B; Pokrajac M; Prostran M
    Vojnosanit Pregl; 2012 Dec; 69(12):1067-75. PubMed ID: 23424961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual task effect on upper and lower extremity skills in different stages of Parkinson's disease.
    Ozcan Gulsen E; Tunca Yilmaz O
    Acta Neurol Belg; 2023 Jun; 123(3):865-872. PubMed ID: 35776407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease.
    Goetz CG; Leurgans S; Raman R;
    Mov Disord; 2002 Mar; 17(2):283-8. PubMed ID: 11921113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A time-efficient screening tool for activities of daily living functions in Parkinson's disease dementia.
    Sulzer P; Liebig L; Csoti I; Graessel E; Wurster I; Berg D; Liepelt-Scarfone I
    J Clin Exp Neuropsychol; 2020 Oct; 42(8):867-879. PubMed ID: 33043797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attentional dysfunction and the punding spectrum in Parkinson's disease.
    Hinkle JT; Perepezko K; Mills KA; Pontone GM
    Parkinsonism Relat Disord; 2021 Mar; 84():23-28. PubMed ID: 33545553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct cortical and subcortical predictors of Purdue Pegboard decline in Parkinson's disease and atypical parkinsonism.
    Wilkes BJ; Tobin ER; Arpin DJ; Wang WE; Okun MS; Jaffee MS; McFarland NR; Corcos DM; Vaillancourt DE
    NPJ Parkinsons Dis; 2023 Jun; 9(1):85. PubMed ID: 37277372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients.
    Becker S; Bäumer A; Maetzler W; Nussbaum S; Timmers M; Van Nueten L; Salvadore G; Zaunbrecher D; Roeben B; Brockmann K; Streffer J; Berg D; Liepelt-Scarfone I
    J Neuropsychol; 2020 Mar; 14(1):69-84. PubMed ID: 30320954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graphical Tasks to Measure Upper Limb Function in Patients With Parkinson's Disease: Validity and Response to Dopaminergic Medication.
    Smits EJ; Tolonen AJ; Cluitmans L; van Gils M; Zietsma RC; Borgemeester RW; van Laar T; Maurits NM
    IEEE J Biomed Health Inform; 2017 Jan; 21(1):283-289. PubMed ID: 26625435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of characteristics affecting instrumental activities of daily living in Parkinson's disease patients without dementia.
    Choi SM; Yoon GJ; Jung HJ; Kim BC
    Neurol Sci; 2019 Jul; 40(7):1403-1408. PubMed ID: 30931509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
    Siderowf A; McDermott M; Kieburtz K; Blindauer K; Plumb S; Shoulson I;
    Mov Disord; 2002 Jul; 17(4):758-63. PubMed ID: 12210871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of 1 Hz Inhibitory and 5 Hz Excitatory Repetitive Transcranial Magnetic Stimulations in Parkinson's Disease: A Functional Magnetic Resonance Imaging Study.
    Bhat P; Goyal V; Kumaran SS; Srivastava AK; Behari M; Dwivedi SN
    Brain Connect; 2023 May; 13(4):247-263. PubMed ID: 36869613
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale-III in Parkinson's disease.
    Haaxma CA; Bloem BR; Borm GF; Horstink MW
    Mov Disord; 2008 Sep; 23(12):1707-17. PubMed ID: 18649395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of mood and cognition on daily functioning and quality of life in older people living with HIV and people with Parkinson's disease.
    Patel SS; Müller-Oehring EM; DeVaughn S; Fama R; Brontë-Stewart HM; Poston KL; Schulte T
    Neuropsychology; 2021 Oct; 35(7):691-705. PubMed ID: 34323563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computerized testing in Parkinson's disease: Performance deficits in relation to standard clinical measures.
    Flannery SL; Jowett T; Garvey A; Cutfield NJ; Machado L
    J Clin Exp Neuropsychol; 2018 Dec; 40(10):1062-1073. PubMed ID: 29978753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of motor impairment influences quality of life in Parkinson's disease.
    Stewart KC; Fernandez HH; Okun MS; Jacobson CE; Hass CJ
    Mov Disord; 2008 Jul; 23(10):1466-8. PubMed ID: 18546324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of patient rated treatment response with measured improvement in Parkinson's disease.
    Davidson MB; McGhee DJ; Counsell CE
    J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):1001-5. PubMed ID: 22626942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.
    Ribba B; Simuni T; Marek K; Siderowf A; Diack C; Pierrillas PB; Monnet A; Ricci B; Nikolcheva T; Pagano G
    J Parkinsons Dis; 2024; 14(6):1225-1235. PubMed ID: 39058452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.